-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhongsheng Pharmaceutical (002317.SZ): The API drug bramiprazole obtained approval for the marketing application of chemical raw materials

Zhitongcaijing·07/31/2026 09:41:11
Listen to the news

Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) issued an announcement. Guangdong Xianqiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Notice of Approval of the Application for the Marketing Application of Chemical Ingredients” for the active ingredient briprazole approved and issued by the State Drug Administration. Briprazole preparations are used to treat schizophrenia in adults.

This time, the API bryprazole obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”, indicating that the API has met the relevant national drug evaluation technical standards and has been approved for use and sale in domestic formulations. It will enrich the company's specialty API product pipeline and help the company expand the R&D and sales of this variety.